Ticker Hub
NBIX — AI Analysis & Sentiment
5 recent AI-generated analyses for NBIX. Sentiment and confidence insights updated continuously.
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences' real-world data for INGREZZA strengthens its lead asset's profile, reinforcing long-term commercial appeal. This positive d...
May 18, 2026Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Neurocrine Biosciences delivered robust Q1 2026 results with significant revenue growth and EPS outperformance, bolstered by strong product demand....
May 5, 2026Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences' initiation of a Phase 1 study for an obesity drug signals long-term pipeline expansion and diversification into a high-grow...
May 4, 2026Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
Neurocrine's CRENESITY showed durable positive effects in pediatric patients over two years, solidifying the drug's long-term revenue potential and...
May 1, 2026Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neurocrine Biosciences strengthened its leadership with a new CTO, Andrew Ratz, poised to drive strategic expansion into biologics and device-based...
Mar 17, 2026